News

Moderna, Inc. and Mitsubishi Tanabe Pharma Corporation announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine…
Read More...

Roche announced the reintroduction of Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States (US) with…
Read More...

GSK plc and CureVac N.V. announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritise investment and focus their…
Read More...

The European Medicines Agency (EMA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD)…
Read More...

Beacon Therapeutics Holdings Limited announced it has raised $170 million in Series B funding. Forbion led the financing, which included existing investors Syncona Limited, Oxford…
Read More...

Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company announced that Boehringer will be progressing their first-in-class SIRPα immuno-oncology…
Read More...

Navidea Biopharmaceuticals, Inc. a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced disappointing results of an exploratory…
Read More...

Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against a range of malignancies, has announced the execution of an…
Read More...

CureVac N.V. announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need. The…
Read More...

Biogen Inc. has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients…
Read More...

Novo Nordisk announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around DKK 5.7 billion related to the…
Read More...

The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of Daiichi Sankyo and…
Read More...

AbbVie announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for ABBV-951 (foscarbidopa/foslevodopa)…
Read More...

Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that the U.S. Food and Drug…
Read More...

Eli Lilly and Company announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.…
Read More...

AstraZeneca’s Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been approved in Japan for the 1st-line treatment of adult patients with locally…
Read More...

GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Omjjara (momelotinib) for the treatment of myelofibrosis. Omjjara is a once-a-day, oral…
Read More...

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi…
Read More...

AstraZeneca’s Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy has been approved in the US as treatment for adult patients with…
Read More...

Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a fixed combination of amivantamab and…
Read More...